TABLE 4.
Clinical Trials Associated With Chemotherapy Sensitization in GBC
| Potential sensitizer | Targets | N | Phase | Status | Results | Trial ID |
|---|---|---|---|---|---|---|
| Everolimus | mTOR | 152 | Phase 2 | Unknown status | — | NCT02836847 |
| Leucovorin calcium | — | 42 | Phase 2 | Completed | — | NCT00009893 |
| 3-AP | RNR | 33 | Phase 2 | Completed | Negative | NCT00075504 |
| M7824 | TGF-β+PD-L1 | 314 | Phase 2 Phase 3 | Active, not recruiting | — | NCT04066491 |
| MEK 162 | MEK | 0 | Phase 1 | Withdrawn | — | NCT02105350 |
| Selumetinib | MEK 1/2 | 57 | Phase 2 | Active, not recruiting | — | NCT02151084 |
| NUC-1031 | — | 21 | Phase 1 | Completed | Positive | NCT02351765 |
| Copanlisib | PI3K | 24 | Phase 2 | Completed | Negative | NCT02631590 |
| MK-2206 | Akt | 0 | Phase 2 | Withdrawn | — | NCT01859182 |
| ADH-1 | N-Cadherin | 17 | Phase 1 | Completed | — | NCT01825603 |
5-FU indicates 5-fluorouracil; CDDP, cisplatin; cli, clinical research; Dox, doxorubicin; DTX, docetaxel; GBC, gallbladder cancer; GEM, gemcitabine; KD, knockdown; KO, knockout; OE, overexpress; OXA, oxaliplatin; vtr, in vitro; vvo, in vivo.
Data were obtained from https://clinicaltrials.gov (accessed August 20, 2022).